Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics Debuts With $47 Million Series A Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$15.0 million","newsHeadline":"LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","amount":"$83.5 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Graphite Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics and Graphite Bio Announce Merger Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Graphite Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by LENZ Therapeutics

    Menu

    LENZ Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              LENZ Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

              Details:

              LNZ101 is a fixed dose opthalmic solution of aceclidine (mAChRs agonist) & brimonidine (ADRA2 agonist), which is being evaluated for the treatment of presbyopia.

              Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate

              Therapeutic Area: Ophthalmology Product Name: LNZ101

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LENZ Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

              Details:

              The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.

              Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate

              Therapeutic Area: Ophthalmology Product Name: LNZ101

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Graphite Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger March 21, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LENZ Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LENZ Therapeutics and Graphite Bio Announce Merger Agreement

              Details:

              The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.

              Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate

              Therapeutic Area: Ophthalmology Product Name: LNZ101

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Graphite Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger November 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LENZ Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies

              Details:

              The Proceeds will enable LENZ to complete the development and registration and, pending approval, launch LNZ100 (aceclidine) and LNZ101 (aceclidine and brimonidine) in the United States.

              Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate

              Therapeutic Area: Ophthalmology Product Name: LNZ101

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sectoral Asset Management

              Deal Size: $83.5 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing March 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LENZ Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia

              Details:

              Both LNZ100 (aceclidine), and LNZ101 (aceclidine + brimonidine) maintained statistical significance of three-line or greater improvement compared to vehicle for all timepoints including the last measured at 10 hours, 37% and 48% respectively.

              Lead Product(s): Brimonidine Tartrate,Aceclidine Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: LNZ101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LENZ Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

              Details:

              The investment by RTW promise LENZ to emerge as a global leader based on its potential best-in-class aceclidine presbyopia eye drop. Aceclidine is a small molecule acetylcholine receptor agonist that causes pupil contraction, creating pinhole effect that improves near vision.

              Lead Product(s): Aceclidine Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: LNZ100

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: RTW Investments

              Deal Size: $10.0 million Upfront Cash: Undisclosed

              Deal Type: Financing April 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LENZ Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

              Details:

              Under the license agreement with Ji Xing Pharmaceuticals, LENZ will develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia in Greater China.

              Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate

              Therapeutic Area: Ophthalmology Product Name: LNZ101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ji Xing Pharmaceuticals

              Deal Size: $110.0 million Upfront Cash: $15.0 million

              Deal Type: Licensing Agreement April 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LENZ Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LENZ Therapeutics Debuts With $47 Million Series A Financing

              Details:

              LENZ Therapeutics (formerly Presbyopia Therapies) is developing a proprietary eye drop formulation of aceclidine. Aceclidine is an NCE in the U.S. and has an established safety profile from its prior use in Europe for glaucoma.

              Lead Product(s): Aceclidine Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: PRX-100

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Versant Ventures

              Deal Size: $47.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing June 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY